Synthetic Glycovaccine Protects against the Bite ofLeishmania‐Infected Sand Flies
Open Access
- 15 August 2006
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 194 (4), 512-518
- https://doi.org/10.1086/505584
Abstract
Leishmaniasis is a vectorborne disease transmitted to human and other mammalian hosts by sand fly bite. In the present study, we show that immunization with Leishmania mexicana promastigote secretory gel (PSG) or with a chemically defined synthetic glycovaccine containing the glycans found in L. mexicana PSG can provide significant protection against challenge by the bite of infected sand flies. Only the glycan from L. mexicana was protective; those from other species did not protect against L. mexicana infection. Furthermore, neither PSG nor the glycovaccine protected against artificial needle challenge, which is traditionally used in antileishmanial vaccine development. Conversely, an antigen preparation that was effective against needle challenge offered no protection against sand fly bite. These findings provide a new target for Leishmania vaccine development and demonstrate the critical role that the vector plays in the evaluation of candidate vaccines for leishmaniasis and other vectorborne diseasesKeywords
This publication has 40 references indexed in Scilit:
- Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease?Immunological Reviews, 2004
- Re‐examination of the immunosuppressive mechanisms mediating non‐cure of Leishmania infection in miceImmunological Reviews, 2004
- The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine developmentImmunological Reviews, 2004
- Inhibition of Lipopolysaccharide-Induced Macrophage IL-12 Production byLeishmania mexicanaAmastigotes: The Role of Cysteine Peptidases and the NF-κB Signaling PathwayThe Journal of Immunology, 2004
- New Insights into the Developmental Biology and Transmission Mechanisms of LeishmaniaCurrent Molecular Medicine, 2004
- A Synthetic Conjugate Polysaccharide Vaccine Against Haemophilus influenzae Type bScience, 2004
- Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasisVaccine, 2004
- Bacterial polysaccharide–protein conjugate vaccinesBritish Medical Bulletin, 2004
- Persistence Without Pathology in Phosphoglycan-Deficient Leishmania majorScience, 2003
- Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes.The Journal of Immunology, 1987